BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 32739163)

  • 1. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
    Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
    J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
    Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
    J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
    Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
    Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
    BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
    Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
    J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy.
    Wahl SGF; Dai HY; Emdal EF; Ottestad AL; Dale VG; Richardsen E; Halvorsen TO; Grønberg BH
    J Pathol Clin Res; 2021 May; 7(3):209-219. PubMed ID: 33502820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
    Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
    Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
    Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
    Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features.
    Cao H; Ma Z; Li Y; Zhang Y; Chen H
    J Thorac Cardiovasc Surg; 2023 Dec; 166(6):e479-e499. PubMed ID: 37142051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma.
    Villaruz LC; Socinski MA; Cunningham DE; Chiosea SI; Burns TF; Siegfried JM; Dacic S
    Cancer; 2013 Jun; 119(12):2268-74. PubMed ID: 23526491
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Jones GD; Caso R; Tan KS; Mastrogiacomo B; Sanchez-Vega F; Liu Y; Connolly JG; Murciano-Goroff YR; Bott MJ; Adusumilli PS; Molena D; Rocco G; Rusch VW; Sihag S; Misale S; Yaeger R; Drilon A; Arbour KC; Riely GJ; Rosen N; Lito P; Zhang H; Lyden DC; Rudin CM; Jones DR; Li BT; Isbell JM
    Clin Cancer Res; 2021 May; 27(9):2604-2612. PubMed ID: 33593884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value.
    Wang H; Schabath MB; Liu Y; Stringfield O; Balagurunathan Y; Heine JJ; Eschrich SA; Ye Z; Gillies RJ
    Clin Lung Cancer; 2016 Jul; 17(4):271-8. PubMed ID: 26712103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
    Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
    Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
    Paik PK; Johnson ML; D'Angelo SP; Sima CS; Ang D; Dogan S; Miller VA; Ladanyi M; Kris MG; Riely GJ
    Cancer; 2012 Dec; 118(23):5840-7. PubMed ID: 22605530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.
    Cao H; Ma Z; Huang Q; Han H; Li Y; Zhang Y; Chen H
    Eur J Cancer; 2024 May; 202():113985. PubMed ID: 38452722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
    Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G
    Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura.
    Raparia K; Villa C; Raj R; Cagle PT
    Arch Pathol Lab Med; 2015 Feb; 139(2):189-93. PubMed ID: 24694341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.